Press Releases

All
Smart Stories
All
Press Releases
All
Factsheets

Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology

November 5, 2021

Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell™) for AML and ALL.

October 13, 2021

TNFα-supplemented DL-4 culture system supports first-in-clinic Smart Immune ProTcell™ technology for immuno-deficient patients fighting cancers and infections

September 29, 2021

Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell progenitor Product SMART 101 (ProTcell™) for AML and ALL.

May 10, 2021

Smart Immune Announces the Launch of its T Cell Progenitor-based Platform of Next-Generation Biotherapies for Severe Infections and Leukemia

January 22, 2020